efavirenz has been researched along with HIV-Associated Lipodystrophy Syndrome in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (80.00) | 29.6817 |
| 2010's | 5 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonfanti, P; De Socio, GV; Di Biagio, A; Gulminetti, R; Madeddu, G; Maggi, P; Martinelli, C; Menzaghi, B; Orofino, G; Ricci, E; Squillace, N; Taramasso, L; Tatarelli, P; Vichi, F | 1 |
| Domingo, JC; Domingo, P; Gallego-Escuredo, JM; Giralt, M; Gutierrez, Mdel M; Lamarca, K; Mateo, MG; Torres, F; Vidal, F; Villarroya, F; Villarroya, J | 1 |
| Butcher, DL; DiRienzo, AG; Garren, KW; Haas, DW; Haubrich, RH; Havlir, DV; Klingman, K; Komarow, L; Mellors, JW; Powderly, WG; Riddler, SA; Rooney, JF | 1 |
| Ebrahimi, R; Ewan, J; Fisher, M; Kingston, M; Liu, H; Moyle, GJ; Orkin, C; Reilly, G; Shahmanesh, M; Wilkins, E | 1 |
| Arribas López, JR | 1 |
| Boothby, M; Gathercole, LL; McGee, KC; McTernan, PG; Nightingale, P; Shahmanesh, M; Shojaee-Moradie, F; Tomlinson, JW; Umpleby, AM | 1 |
| Hanke, CW; Tierney, EP | 1 |
| Baldi, A; Chirianni, A; De Luca, A; Esposito, V; Gargiulo, M; Lucariello, A; Manente, L; Parrella, G; Parrella, R; Perna, A; Viglietti, R | 1 |
| Collier, AC; Daar, ES; Fichtenbaum, CJ; Fink, H; Gerschenson, M; Kosmiski, L; Libutti, DE; McComsey, GA; O'Riordan, M; Santana, JL; Sax, PE | 1 |
| Fessel, WJ; Follansbee, SE; Rego, J | 1 |
| Oka, S; Teruya, K | 1 |
| Boyle, BA | 1 |
| Holzman, R; Maslow, M; Ortiz, O; Rahim, S | 1 |
| Mallal, S; Nolan, D; Reiss, P | 1 |
| Dubé, MP; Grinspoon, SK; Meyer, WA; Mulligan, K; Parker, RA; Robbins, GK; Roubenoff, R; Shafer, RW; Snyder, SW; Tebas, P; Wininger, DA; Zackin, RA | 1 |
| Nolan, D | 1 |
| Arathoon, E; Arlotti, M; Giordano, M; Jemsek, JG; Noor, MA; Perez, C; Pokrovskiy, V; Soccodato, M; Sosa, N; Thiry, A | 1 |
| Antoniadou, A; Giamarellou, H; Katsarolis, I; Panagopoulos, P; Papadopoulos, A; Poulakou, G; Tsiodras, S | 1 |
| Hall, DB; Lange, JM; Reiss, P; van Leth, F | 1 |
| Alonso, C; Aranda, M; Barrufet, P; Berenguer, J; Crespo, M; del Río, L; Delegido, A; Ferrer, E; Fisac, C; Gatell, JM; Lérida, A; Llibre, JM; Lonca, M; Martínez-Lacasa, J; Merino, E; Niubo, J; Pedreira, JD; Podzamczer, D; Pulido, F; Ribas, MA; Ribera, E; Rubio, R; Sanchez, P; Sanz, J; Veloso, S | 1 |
| Brizz, B; Collier, AC; Evans, S; Feinberg, J; Fischl, MA; Sattler, F; Shevitz, A; Shikuma, C; Tebas, P; Yarasheski, K; Zhang, J | 1 |
| Dubé, MP; Grinspoon, SK; Komarow, L; Mulligan, K; Parker, RA; Robbins, GK; Roubenoff, R; Tebas, P | 1 |
| Borgonovo, S; Brambilla, P; Cafarelli, L; Giacomet, V; Mora, S; Viganò, A; Zamproni, I; Zuccotti, G | 1 |
| Autar, RS; Boyd, MA; Burger, DM; Cooper, DA; Lange, J; Phanuphak, P; Reiss, P; Ruxrungthams, K; Sankote, J; Wit, FW | 1 |
| Domingo, P; Martínez, E; Moreno, S; Pérez-Molina, JA | 1 |
7 review(s) available for efavirenz and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
[The "induction-maintenance" strategy].
Topics: Adipose Tissue; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Virus Replication; Zidovudine | 2008 |
"Bullfrog neck," a unique morphologic trait in HIV lipodystrophy: case series and review of the literature.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Middle Aged; Neck; Reverse Transcriptase Inhibitors | 2010 |
[Antiretrovirals].
Topics: Acidosis, Lactic; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Hemophilia A; Hemorrhage; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Indinavir; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2003 |
Issues in antiretroviral toxicity.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Exanthema; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Nevirapine; Oxazines; Pregnancy; Quality of Life; Randomized Controlled Trials as Topic | 2003 |
Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardiovascular Diseases; Cyclopropanes; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Kidney Diseases; Lopinavir; Metabolic Syndrome; Nevirapine; Organophosphonates; Oxazines; Pyrimidinones; Risk Factors; Tenofovir | 2005 |
Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Cardiovascular Diseases; Cyclopropanes; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Metabolic Syndrome; Nevirapine; Oxazines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Risk Factors; Stavudine; Zidovudine | 2005 |
The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2008 |
12 trial(s) available for efavirenz and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Gene Expression Regulation; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Organophosphonates; Ritonavir; Subcutaneous Fat; Tenofovir; Transcriptome | 2014 |
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.
Topics: Absorptiometry, Photon; Adult; Alkynes; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lipid Metabolism; Lopinavir; Male; Pyrimidinones; Ritonavir | 2009 |
A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals.
Topics: Adenine; Adipose Tissue; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Extremities; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lipids; Male; Middle Aged; Organophosphonates; Tenofovir; Young Adult; Zidovudine | 2009 |
Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months.
Topics: Adenine; Adipocytes; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cell Differentiation; Cyclopropanes; Drug Therapy, Combination; Fatty Acids; Female; Gene Expression; Genes, Mitochondrial; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Up-Regulation; Zidovudine | 2009 |
Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
Topics: Adenine; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; DNA, Mitochondrial; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Mitochondria; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2013 |
High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: implications for pathogenesis of fat redistribution.
Topics: Adipose Tissue; Alkynes; Anti-HIV Agents; Benzoxazines; Body Composition; Cholesterol, HDL; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Hypolipidemic Agents; Niacin; Oxazines; Reverse Transcriptase Inhibitors; Surveys and Questionnaires | 2002 |
Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Blood Glucose; Cyclopropanes; Drug Therapy, Combination; Dyslipidemias; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Insulin Resistance; Lipids; Male; Nelfinavir; Nucleosides; Oxazines | 2005 |
Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients.
Topics: Adiposity; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Oligopeptides; Oxazines; Pyridines; Zidovudine | 2006 |
Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Aged; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Extremities; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lipid Metabolism; Lipids; Male; Middle Aged; Oxazines; Stavudine; Viral Load | 2007 |
Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Fat Distribution; Cyclopropanes; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Male; Pyrimidinones; Ritonavir; Time Factors | 2007 |
Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.
Topics: Absorptiometry, Photon; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Composition; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Prospective Studies; Stavudine; Time Factors; Treatment Outcome; United States; Zidovudine | 2007 |
Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atrophy; Benzoxazines; Body Composition; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Female; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Italy; Male; Organophosphonates; Prospective Studies; Protease Inhibitors; Stavudine; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2007 |
6 other study(ies) available for efavirenz and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA).
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Integrase Inhibitors; Lipid Metabolism; Lipids; Male; Middle Aged; Oxazines; Piperazines; Protease Inhibitors; Pyridones; Rilpivirine; Ritonavir; Treatment Outcome | 2018 |
Role of FAP48 in HIV-associated lipodystrophy.
Topics: Adaptor Proteins, Signal Transducing; Adipocytes; Alkynes; Animals; Antiretroviral Therapy, Highly Active; Benzoxazines; Calcineurin; Carbamates; Cell Differentiation; Cell Line; Cyclopropanes; Furans; Gene Expression; Glucocorticoids; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Indinavir; Mice; Saquinavir; Signal Transduction; Stavudine; Sulfonamides; Transfection | 2012 |
A case-control study of gynecomastia in HIV-1-infected patients receiving HAART.
Topics: Adult; Aged; Alkynes; Analysis of Variance; Antiretroviral Therapy, Highly Active; Benzoxazines; Case-Control Studies; CD4 Lymphocyte Count; Cyclopropanes; Gynecomastia; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Logistic Models; Male; Middle Aged; New York City; Oxazines; Risk Factors; Testosterone; Time Factors; Treatment Outcome | 2004 |
Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.
Topics: Adult; Aged; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Male; Middle Aged; Oxazines; Pyrimidinones; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Triglycerides; Viral Load | 2006 |
Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cholesterol; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lipids; Lipoproteins; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Stavudine; Triglycerides | 2006 |
Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen.
Topics: Adipose Tissue; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Composition; Body Fat Distribution; Body Mass Index; Cholesterol; Cholesterol, HDL; Cyclopropanes; Extremities; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Indinavir; Intra-Abdominal Fat; Male; Reverse Transcriptase Inhibitors; Ritonavir; Thailand; Triglycerides | 2007 |